Renzoku Biologics Inc. (Headquarters: Chiyoda-ku, Tokyo; Representative Director: Hitoshi Kuboniwa; hereinafter “the Company”) has decided to construct a cGMP manufacturing facility capable of handling both investigational drug manufacturing and commercial production within Logicross Sagamihara in Sagamihara City, Kanagawa Prefecture. Construction of the facility is scheduled to begin in September 2026, with operations set to commence in 2028.
This facility is designed to support contract manufacturing of antibody drug substances, the Company’s core business. The facility will cover the entire process from cell culture to purification and will employ advanced manufacturing technologies, including continuous production, to achieve manufacturing with superior production efficiency, quality, and flexibility. Additionally, a process development research facility, including cell line development, will be co-located within the site.
Our vision is to “Aiming to be a CDMO, which provides values globally, by realizing “Advanced Biomanufacturing Factory” integrated innovative technologies such as continuous manufacturing, and to be a CDMO which provides values as a Center of Excellence (CoE) that brings innovation to antibody drug manufacturing.” Through the construction of this facility, we will meet pharmaceutical development and manufacturing needs around the globe and will contribute to the stable supply of antibody drugs required by patients.